Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT04905706
Recruiting Observational

3D Laparoscopic Adrenalectomies for Adrenal Tumors

NCT04905706 · tracked via the Priya Life Science Spain tracker
Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Phase
Observational
Started
2013-01-01
Last updated
2025-05-09

Condition(s) studied

Adrenal TumorAdrenalectomy; Status

Study summary

The main drawbacks of conventional 2D laparoscopy are limited depth perception and loss of spatial orientation. High-quality 3D laparoscopy systems might improve surgical outcomes for adrenalectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All adult patients (age ≥ 18 years) * Patients diagnosed with adrenal masses (benign and malignant tumors) * Underwent a unilateral 3D laparoscopic adrenalectomy from January 2013 to December 2033. Exclusion Criteria: * Emergency surgery. * Open adrenalectomy. * Bilateral adrenalectomies (open or laparoscopy). * Patients who underwent laparoscopic adrenalectomy together with another laparoscopic surgical procedure in the same intervention. * Patients without complete follow-up for at least 30 days after hospital discharge.

Primary outcome measure(s)

  • Postoperative complications rate of 3D laparoscopic adrenalectomy — Within 30 days after surgery
    Rate of medical and surgical complications within 30 days after surgery using the Dindo-Clavien classification, described as: Grade I = Any deviation from the normal postoperative course. Grade 2 = Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III = Requiring surgical, endoscopic or radiological intervention, not under (Grade IIIa) or under general anesthesia (Grade IIIb) Grade IV = Life-threatening complication with single organ (Grade IVa) or Multiorgan dysfunction (Grade IVb) Grade V = Death of a patient.
  • Length of hospital stay — Up to 4 weeks
    Total length of hospital stay will be recorded in days beginning at admission for surgery until discharge (number of days) .

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitari Dr. Josep Trueta de Girona Girona Girona Recruiting

More Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta trials in Spain

Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis Recruiting
Inter-relationships Among Glucose, Brain, Gut Microbiota and MicroRNAs (IRONmiRNA). Active, not recruiting
Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis Recruiting
Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection. Recruiting
The Effect of the Movement Imitation Therapy in Preterm (MIT-PB) in Motor Behavior's Quality. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04905706 on ClinicalTrials.gov ↗ ← All trials in Spain